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Abstract 
Objective: Considering the demonstrated implication of the retina in PD pathology and the 
importance of dopaminergic cells in this tissue, we aimed to analyze the state of the dopaminergic 
amacrine cells and some of their main post-synaptic neurons in the retina of PD.  
Methods: Using immunohistochemistry and confocal microscopy, we evaluated morphology, 
number, and synaptic connections of dopaminergic cells and their post-synaptic cells, AII 
amacrine and melanopsin-containing retinal ganglion cells, in control and PD eyes from human 
donors.  
Results: In PD, dopaminergic amacrine cell number was reduced between 58% and 26% in 
different retinal regions, involving a decline in the number of synaptic contacts with AII amacrine 
cells (by 60%) and melanopsin cells (by 35%). Despite losing their main synaptic input, AII cells 
were not reduced in number, but they showed cellular alterations compromising their adequate 
function: i) a loss of mitochondria inside their lobular appendages, that may indicate an energetic 
failure and ii) a loss of connexin 36, suggesting alterations in the AII coupling and in visual signal 
transmission from the rod pathway.  
Interpretation: The dopaminergic system impairment and the affection of the rod pathway 
through the AII cells may explain and be partially responsible for the reduced contrast sensitivity 
or electroretinographic response described in PD. Also, dopamine reduction and the loss of 
synaptic contacts with melanopsin cells may contribute to the melanopsin retinal ganglion cell 
loss previously described and to the disturbances in circadian rhythm and sleep reported in PD 
patients. These data support the idea that the retina reproduces brain neurodegeneration and is 
highly involved in PD pathology.  
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Introduction 
Parkinson’s disease (PD) is a common neurodegenerative disorder traditionally characterized by 
the presence of Lewy bodies in the brain and by the degeneration of mesencephalic dopaminergic 
neurons in the substantia nigra pars compacta, that leads to a depletion of dopamine in the 
striatum and to the subsequent motor alterations1. Although classically considered as a brain-
predominant disease, recent growing evidence supports the involvement of peripheral and 
extracranial organs in PD. Among them, the retina has been recently proposed to reflect the PD 
brain pathology: phosphorylated-α-synuclein deposits, similar to Lewy bodies, have been found 
in the retina of PD patients, whose density correlated with disease severity2,3. In addition, PD 
patients present several visual symptoms such as reduced amplitudes in b-waves and oscillatory 
potentials in electroretinograms, reduced visual evoked potentials, inner retinal layer thinning by 
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optical coherence tomography (OCT) 4, impaired motion perception, contrast sensitivity and color 
discrimination5–8, circadian rhythm dysfunction9,10 and melanopsin-containing retinal ganglion 
cell (mRGC) degeneration11. 
Considering the described similarities between the neurodegenerative process in the retina and 
brain, it is natural to wonder if the dopaminergic cells in the retina are involved in the disease as 
they are in the brain. In the retina, dopamine is an essential neuromodulator that has widespread 
influences on retinal function and regulation. Among their main functions, dopaminergic 
amacrine cells regulate the light/dark adaptation, modulating and reshaping retinal circuitries 
depending on light conditions. The sustained dopaminergic light responses are regulated by 
mRGC12,13 and, at the same time, some mRGC are directly post-synaptic to dopaminergic 
amacrine cells14,15, creating a complex regulatory network. 
Also, dopaminergic cells are involved in the regulation of the rod pathway through the 
coupling/uncoupling of the AII amacrine cells16. In scotopic conditions, AII amacrine cells are 
coupled with other AII cells and with ON cone bipolar cells by homotypic and heterotypic 
connexin 36 gap junctions17, and they add the rod-pathway information into the cone-pathway18. 
In photopic conditions, dopamine release is stimulated, and dopaminergic processes make 
synaptic contacts onto AII cell bodies and lobular appendages, uncoupling AII from their 
contacts19,20. Given its importance in regulating retinal function21, an impairment in the retinal 
dopaminergic system of PD patients may lead to severe retinal dysfunctions like those previously 
mentioned. 
It is accepted that the retina is highly affected in PD but, whether or not dopaminergic amacrine 
cells degenerate in the retina of PD patients, as happens in the brain, remains unknown. The aim 
of this work is to analyze the state of the dopaminergic amacrine cells in the retinas of PD patients 
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compared to controls, and the relationship with their main post-synaptic neurons: AII amacrine 
cells and mRGC.  
 
Materials and methods 
Source of human subjects and clinical characterization 
Retinas from human donors were obtained post-mortem from volunteers in the Arizona Study of 
Aging and Neurodegenerative Disorders (AZSAND)/ Banner Sun Health Research Institute Brain 
and Body Donation Program (BBDP; https://www.brainandbodydonationprogram.org)22 and 
from the Hospital General Universitario de Alicante (HGUA). All procedures involving humans 
followed the Declaration of Helsinki (Code of Ethics of the World Medical Association) and were 
approved by the Ethics Committee of the University of Alicante (UA-2018-04-17). All 
participants signed written informed consent prior to their enrolment in AZSAND. Donors did 
not significantly differ in age, being from 69 to 88 years old at the time of death, and did not 
report previous ophthalmological pathologies. Participants in the study were clinically 
characterized by standard tests assessing neurological components as previously described23,24. 
Individuals diagnosed with Parkinson’s disease belong to the PD group (n=8; 76.3±5.55 years 
old; AZSAND) and healthy individuals, without neurodegenerative or ocular diseases, to the 
control group (n=5; 72.6±1.9 years old; HGUA). ¿INCLUIR TABLA CON INFORMACION DE 
PACIENTES? 
Retinal immunohistochemistry 
After enucleation, eyes were fixed in paraformaldehyde (3.75-4%) 2 h at RT or 24-72 h at 4 ºC. 
Then, they were washed in 0.1 M phosphate buffer and cryoprotected in 15%, 20% and 30% 
successive sucrose solutions. Cornea, iris, lens and vitreous body were extracted, and the retina 
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was dissected into eight pieces. The superonasal and the temporal-central pieces were employed 
for subsequent wholemount analysis. In other cases, the temporal-central region was cut in a 
cryostat to obtain vertical sections of 14 microns. Immunohistochemistry in wholemount retinas 
and vertical sections was performed following previously described protocols2. Briefly, retinas 
were washed three times in 0.1 M phosphate buffer and incubated with the primary antibody 
overnight or for 3 nights (in cuts and wholemounts, respectively). Primary antibodies used were 
sheep polyclonal to tyrosine hydroxylase (1:200; AB1542 Merck Millipore, Darmstadt, 
Germany), rabbit polyclonal anti-calretinin (1:200; CR7679 Swant, Marly, Switzerland), mouse 
polyclonal anti-cytochrome C (1:100; Zymed, San Francisco, CA, USA), mouse polyclonal anti-
connexin 36 (1:200; MAB3045 Merck Millipore, Darmstadt, Germany) and rabbit polyclonal 
anti-melanopsin (1:1000; UF028 kindly provided by Dr. Ignacio Provencio, University of 
Virginia, Charlotesville, VA, USA)25. After the incubation time, they were washed and incubated 
with secondary antibodies at a dilution 1:100 for 1 h or 2 nights in cuts or in wholemounts, 
respectively. The polyclonal secondary antibodies used were: donkey anti-rabbit conjugated to 
Alexa-555 (A31572), donkey anti-sheep conjugated to Alexa-488 (A11015), and donkey anti-
mouse conjugated to Alexa-488 (A21201; all from ThermoFisher Scientific, Rockford, USA). 
Samples were washed again, wholemount retinas were disposed with the ganglion cell layer side 
up, and all samples were mounted in Citifluor (Citifluor Ltd, London, UK) and coverslipped. 
Fluorescence images were obtained using a Leica confocal microscope TCS SP8 (Leica 
Microsystems, Wetzlar, Germany). 
Antibody characterization 
The sheep polyclonal anti-tyrosine hydroxylase (AB1542, Merck Millipore) was generated 
against the native tyrosine hydroxylase protein from rat pheochromocytoma and it has been 
previously characterized by immunohistochemistry in the rat and mouse retina26,27. Its staining 
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pattern in the human retina is comparable to that of other species such as squirrel, cat, or rat20,26,28, 
and the density and distribution of control human dopaminergic cells when stained with this 
antibody is comparable to previous studies done in other primates29,30. Also, the dopaminergic 
staining pattern observed is the same as the obtained with other anti-tyrosine hydroxylase 
antibodies (ab112, Abcam, Cambridge, UK, data not shown). 
The rabbit polyclonal anti-calretinin (CR7679, Swant) was produced by immunization with 
recombinant human calretinin containing a 6-his tag at the N-terminal. The manufacturer provides 
its characterization by western blot on brain lysates and by immunohistochemistry in mice brain, 
and it has also been characterized by immunohistochemistry in the human retina31. 
The mouse polyclonal anti-cytochrome C (Zymed) was generated against the rat cytochrome C 
protein and has been previously characterized by immunohistochemistry in the human retina32.  
The mouse polyclonal anti-connexin 36 (MAB3045, Merck Millipore) was produced against the 
perch connexin 35 and, according to the manufacturer, recognizes primate connexin 36, the gene 
homologue to connexin 35. It has been previously characterized by immunohistochemistry in the 
retina33.  
Finally, the rabbit polyclonal anti-melanopsin antiserum (gift from Dr. Provencio) was raised 
against the 15 N-terminal amino acids of the human melanopsin protein and has been 
characterized by immunohistochemistry in the human retina11,34. 
Cellular quantification 
Confocal images of flat retinas were used to assess the morphology and density of dopaminergic 
and AII amacrine cells, and the number of connections between dopaminergic and AII amacrine 
cells or mRGC. Photographs of wholemount retinas were obtained using the tiles module in a 
TCS SP8 Leica confocal. The total number of dopaminergic or AII amacrine cells was counted 
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in the whole retinal quadrant, the area of the quadrant was measured, and the density of cells per 
mm2 was calculated as the number of cells/area of retina. The area of the measured retinal pieces 
ranged from 80 to 150 mm2 in the central-temporal quadrant and from 32 to 97 mm2 in the 
superonasal quadrants.  Density maps of dopaminergic cells in the temporal-central quadrant and 
in a representative area of the superonasal quadrant were made using the ggplot235 package in R 
version 3.6 (R Core Team 2019). 
 The number of dopaminergic contacts with AII cells was measured in, at least, 20 frames 
randomly distributed in each retina and expressed as the number of contacts per AII cell. The 
number of dopaminergic contacts with melanopsin dendrites was counted and divided per 
dendrite length, calculating the value of dopaminergic contacts per 100 µm of melanopsin 
dendrites in, at least, 15 frames randomly distributed per retina.  
Statistical analysis 
Statistical analysis was performed using the GraphPad Prism software (version 6; Graph- Pad 
Software Inc., San Diego, CA). Non-parametric two-tailed Mann-Whitney tests were used to 
determine the differences of the analyzed variables between the two groups considered: PD and 
control. Values are presented in boxplots made using the ggplot235 package: the box shows the 
interquartile range and the line dividing the box represents the median of the data. In all cases, 
the significance level was set at P<0.05. 
 
Results 
Dopaminergic cell degeneration 
Dopamine-containing cells in the retina of healthy subjects are wide field amacrine cells that 
extend their thin and ramified dendrites long distances creating a dense plexus36. Dopaminergic 
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cells frequently make contacts with the soma of their post-synaptic neurons at the S1 strata of the 
inner plexiform layer (IPL). In healthy individuals, this high density of contacts around post-
synaptic cell bodies creates ring-like structures that can be observed in the dopaminergic plexus 
(Fig. 1A, arrows). Due to their wide retinal neuromodulatory function, dopaminergic dendrites 
not only stratify at the S1 strata (Fig. 1C), but also, although to a lesser extent, at the IPL S3, and 
even S5 (Fig. 1C, arrowheads), and at the outer plexiform layer (OPL) and outer nuclear layer 
(ONL) (Fig. 1C, arrows) reaching photoreceptor cell bodies. 
By contrast, in PD (Fig. 1B, D), dopaminergic cells display some characteristics of an atrophied 
morphology: dendrites are shorter and thicker, with some swollen fragments (Fig. 1B, 
arrowheads) and their plexus has lost the typical ring structure. Also, almost all the remaining 
dendrites are located at the S1 (Fig. 1D) and very few of them reach the OPL, ONL (Fig. 1D, 
arrows) the S3 or the S5 (Fig. 1D, arrowheads), probably inducing a loss of dopamine in these 
regions. 
In healthy primates, dopaminergic amacrine cell distribution is equivalent in all quadrants, as they 
are symmetrically distributed around the fovea. They are bigger and sparsely distributed in the 
periphery and of smaller size and higher density towards the central retina, reaching their 
maximum density peak at the parafovea29,30. Fig. 2 shows color-coded density maps where the 
white or black dots are the dopaminergic cells, yellow shows the maximum density, and dark blue 
shows the minimum dopaminergic cell density. In controls, dopaminergic cell distribution is 
comparable to the previously described: there is a maximum density peak at the parafovea, with 
45 cells/mm2, that rapidly declines concentrically towards more peripheral locations: in the 
perifovea, the median density is 30 cells/mm2 and in the near periphery (next 3mm from perifovea; 
0-3mm to perifovea in Fig. 2) is 18 cells/mm2 (Fig. 2A, E). The effect of eccentricity in 
dopaminergic density is also observed in the superonasal quadrant (Fig. 2F, H), where the median 
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dopaminergic cell density is 19 cells/mm2 in the most central region and declines to 17 cells/ mm2 
and 14 cells/mm2 towards the periphery. 
In addition to an altered morphology, PD retinas also display a decrease in the dopaminergic cell 
density. Notice that dopaminergic cell density is higher in controls than in PD in the whole central 
quadrant (20.2 cells/mm2 in controls vs 13.1 cells/mm2 in PD) (Fig. 2A-B, E), with strong 
differences in the parafoveal and perifoveal regions. In the parafovea (insets in Fig. 2A-B), 
dopaminergic cell density in PD is reduced by a 58% (45.1 cells/mm2 in controls vs 19.2 
cells/mm2 in PD) and in the perifovea by a 51% (29.7 cells/mm2 in controls vs 14.4 cells/mm2 in 
PD) (Fig. 2E). Fig. 2C-D shows confocal images of control and PD dopaminergic cells at the 
parafovea, where the cell number reduction can be easily observed. No statistical analysis has 
been done in this quadrant due to the small sample size, caused by the difficulty of obtaining 
human fovea tissue.  
In the superonasal quadrant, the dopaminergic cell density was reduced by 45%, changing from 
18.4 cells/mm2 in controls to 10.8 cells/mm2 in PD retinas (P<0.01) (Fig. 2F-H). This decrease 
was statistically significant thorough the whole quadrant, from the most central to the most 
peripheral regions. In the most central area (from 2 to 7mm to the optic nerve) the median 
dopaminergic cell density changed from 19.4 cells/mm2 in healthy subjects to 13.4 cells/mm2 in 
PD patients (P<0.05). Towards the periphery, dopaminergic cell density decreases in both groups 
and the differences are maintained: 17.3 cells/mm2 in controls are reduced to 12.8 cells/mm2 in 
PD in the region between 7 to 11mm to the optic nerve (P<0.05), and, in the most peripheral area 
(from 11 to 16 mm to the optic nerve), 14.4 cells/mm2 in controls change to 8.8 cells/mm2 in PD 
(P<0.01) (Fig. 2F-H). 
Morphological alterations of AII amacrine cells 
This article is protected by copyright. All rights reserved.
  
Double immunostaining using tyrosine hydroxylase (green) and calretinin (red) antibodies 
allowed visualizing the relationship between dopaminergic amacrine cells and their main post-
synaptic neurons: AII amacrine cells. Synaptic contacts from dopaminergic cells to AII amacrine 
cells are so abundant that they make ring-like structures around the cell body (Fig. 3A). In PD, 
probably as a result of the dopaminergic cell degeneration, ring-like structures around AII 
amacrine cells are partially lost (Fig. 3B). The quantification of dopaminergic synaptic contacts 
per AII cell body revealed that these synaptic connections are reduced by 60% (from 9.3 to 3.7) 
in PD patients (Fig. 3C-G). But, despite losing one of their major inputs, AII amacrine cell number 
remains stable in PD compared to controls (Fig. 3H).  
The maintenance of AII amacrine cell number does not discard the possibility that they are 
morphologically or functionally affected by the disease. In order to address this issue, 
characteristic structural features of AII cells, as well as functional implications were assessed. 
In healthy individuals, AII cells are small amacrine cells whose dendrites stratify close to the cell 
body in both sublamina a (OFF) and b (ON) of the IPL (Fig. 4A) while in PD their typical 
morphology and stratification has been partially loss (Fig. 4B). Also, in normal conditions, AII 
cells contain big mitochondria within their lobular appendages that supply them with the energy 
required for their adequate function. Mitochondria (green) inside the AII lobular appendages (red) 
can be observed as yellow dots (arrows) in Fig. 3. These mitochondria are big and abundant in 
control subjects (Fig. 4A, C, E) but they may be affected in PD (Fig. 4B, D, F): the yellow dots 
are less abundant and, when present, they are much smaller than in control retinas.  
Another important characteristic of AII amacrine cells is that, in dark conditions, they are coupled 
to each other and to ON cone bipolar cells by gap junctions. These gap junctions are mediated by 
connexin 36 protein and are located at the ON sublamina of IPL. Fig. 4 shows co-immunostaining 
of AII cells (red) and connexin 36 (green) in retinas of control and PD subjects. In controls (Fig. 
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5A, C, E, G), connexin 36 at AII amacrine cells is abundant and mainly located in the S4 and S5 
strata of the IPL (ON sublamina). Nevertheless, in PD (Fig. 5B, D, F, H), the amount of connexin 
36 immunostaining in the ON sublamina is strongly reduced. 
Reduced dopaminergic synaptic contacts in melanopsin-containing retinal ganglion cells 
Some mRGC types are post-synaptic to dopaminergic amacrine cells, especially the ones that 
stratify in the IPL OFF sublamina (M1 and displaced M1). Double immunohistochemistry using 
antibodies against tyrosine hydroxylase (green) and melanopsin (red) revealed the synaptic 
relationship between dopaminergic and mRGC in the IPL (Fig. 6). The above-mentioned loss of 
the dopaminergic plexus and the previously described impairment of mRGC11 in PD can be 
observed in Fig. 6, where the dopaminergic plexus (in green) is reduced and the mRGC 
morphology (in red) is altered in PD (lower dendritic complexity, shorter dendrites, and reduced 
number of ramifications) (Fig. 6B, D) compared to controls (Fig. 6A, C). In healthy subjects, 
dopaminergic cells make abundant synapses with mRGC dendrites, observed as green dots 
contacting the melanopsin dendrites (in red) in Fig. 6E, F (arrowheads). Nevertheless, probably 
as a consequence of the reduced dopaminergic plexus, the dopaminergic contacts that reach 
mRGC are reduced in PD, although still present (Fig. 6G, H, arrowheads). The numerical 
quantification of these contacts reveals a 35% decrease in PD, changing from 70 contacts per 100 
µm in controls to 43 contacts per 100 µm in PD (P<0.0001) (Fig. 6I). 
 
Discussion 
This study provides, for the first time, a systematic quantification of retinal dopaminergic cells in 
PD patients, demonstrating a loss of these cells and their plexus, involving a global impairment 
of the dopaminergic system. As dopamine is both a neurotransmitter and a broad neuromodulator 
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in the retina37,38, its loss may cause cellular and functional alterations at very different levels. At 
the S1 strata, dopaminergic cells make direct synaptic contacts with AII, A8, A17 and A13 
amacrine cells20,39,40, at the OPL, they regulate the horizontal cell coupling and the cone-rod 
coupling37,38, and they also modulate ganglion cells through direct (as is the case for mRGC) or 
diffuse dopaminergic regulation40,41. Among all of their post-synaptic cells, special attention has 
been given to the AII amacrine cells, involved in the rod pathway41–44.  
Dopaminergic cells and their synaptic contacts to AII amacrine cells are strongly reduced in PD. 
But, although lacking one of their main inputs, AII cell number remains stable. The fact that AII 
cells survive while dopaminergic cells are lost may be interpreted in different ways. First, it may 
reflect that degeneration in PD is somehow specific and preferentially affects specific cell types, 
like dopaminergic or mRGC11. Second, it is possible that the remaining dopamine levels, together 
with additional AII inputs coming from cone and rod bipolar and other amacrine cells44–46, are 
enough to maintain the AII cell number. Third, AII cells may be more resistant to this type of 
neurodegeneration but may eventually degenerate if the disease is prolonged in time or of higher 
severity. Finally, a combination of these three hypotheses may be occurring, and time-course 
studies of PD progression would be needed to clarify this. 
Although AII cells remain, some of their essential cellular components are impaired in the disease, 
which may be reflected in functional alterations. The big mitochondria in their lobular appendages 
are lost or reduced in size, indicating an energetic failure of AII cells in PD. Also, the amount of 
connexin 36 in the IPL ON sublamina is decreased, revealing a failure in AII coupling through 
gap junctions and suggesting a functional impairment in the transmission of the rod-mediated 
visual signals17: if AII cells have a reduced ability to couple, the integration of the rod pathway 
information into the cone pathway would be deficient. In normal conditions, the reduction of 
dopamine levels during dark hours results in increasing AII coupling16,40,41. In PD,  two possible 
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processes may have occurred: 1) as a result of dopamine loss, AII cells are continuously coupled, 
which induces down-regulation of connexin 36 expression and/or energetic unbalance 
accompanied by mitochondrial failure, 2) as PD reduces mitochondrial viability47, AII 
mitochondria may be lost as a direct consequence of the disease and induce a functional 
impairment of AII cells losing their coupling proteins. Again, time-course research is needed to 
understand the progression and relationship of the cellular changes observed. 
Dopaminergic cells also play an important role in regulating the retinal dark to light adaptation 
and the circadian rhythm40. In a bidirectional way, the sustained dopaminergic response to light 
is regulated by mRGC12,13 and, at the same time, mRGC in the IPL sublamina OFF are directly 
post-synaptic to dopaminergic cells and are subjected to dopaminergic modulation14,15. Thus, 
considering the close relationship between dopamine and mRGC, the dopaminergic cell 
degeneration and the loss of synaptic contacts reported here may be one of the causes of the 
impairment of mRGC described in the disease and may contribute to the circadian rhythm 
dysfunction and sleep problems reported in patients11. In a retrograde way, the loss of the mRGC 
may also accelerate the dopaminergic degeneration.  
Our results are in accordance with previous data that suggested a possible role of dopaminergic 
retinal cells in PD48–50. The levels of retinal dopamine are decreased in patients 50 and in MPTP-
treated rabbits51 and monkeys52. Also, the degeneration of dopaminergic amacrine cells has been 
described in PD animal models, such as MPTP-treated mice53–55 and monkeys56, rotenone-treated 
rats57,58, 6-OHDA-treated rats59 and mice overexpressing α-synuclein60. This first systematic 
study regarding dopaminergic amacrine cells in the human retina of PD patients demonstrates that 
animal models previously used in the literature accurately reflect the state of the dopaminergic 
system in the retina, since they present similar alterations, and indicate that these models are 
useful for further studies. 
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Nevertheless, in contrast with what happens in the brain, previous studies had not found 
phosphorylated-α-synuclein deposits within retinal dopaminergic cells in patients suffering from 
PD2,3,61. We and others have always found scarce and sparse retinal phosphorylated-α-synuclein 
deposits in the ganglion cell layer, and never within dopaminergic cells. This fact suggests that 
dopaminergic cell death in the retina is independent of a self-accumulation of phosphorylated-α-
synuclein or that the levels of phosphorylated-α-synuclein are low and the techniques used are 
not able to detect it. 
Overall, the present results suggest that the retina is highly affected during PD neurodegeneration. 
This retinal impairment may explain some of the visual deficits described in patients. For 
example, altered coupling and uncoupling of the horizontal cells as a result of the dopaminergic 
impairment may underlie the diminished contrast sensitivity described in patients6,62–64 and the 
ERG oscillatory potentials reduction may reflect alterations in dopaminergic cells and/or in their 
interactions with other amacrine, bipolar and ganglion cells7. In addition, as Müller and bipolar 
cells also present dopamine receptors65, they are subjected to dopamine modulation: lower 
dopamine levels may be involved in the reduction of the ERG b-wave (that mainly reflects the 
state of bipolar cells and their interaction with Müller cells) observed in patients7 or after 
dopamine receptor blockage66. Also, the loss of connexin 36 described in the present work and 
the consequent impairment in signal transmission from the rod to the cone pathway17 may cause 
alterations in cone bipolar cells activity, probably affecting the ERG b-wave. Finally, using OCT, 
some authors have described a thinning of the nerve fiber layer67, nerve fiber layer + ganglion cell 
layer + IPL49, or ganglion cell layer + IPL4, and this suggests a possible role of dopamine 
deficiency in the structural remodeling of these bands, although the current data is still 
inconclusive and other authors have not found these changes7. 
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Interestingly, it has recently been proposed that retinal affection may have important implications 
not only in visual dysfunctions but also in some of the motor symptoms. Willis and colleagues68 
have observed that animal models intravitreally injected with minimal doses of MPTP, 6OHDA, 
rotenone or paraquat, displayed motor impairment without having brain affection. Other studies 
using L-DOPA in the retina showed an improvement of the motor symptoms69, and so did timed 
light therapy that, besides enhancing sleep, mood and anxiety, also improved motor function70 
probably by a dopamine release stimulation and by partially restoring circadian rhythms through 
mRGC function improvement71,72.  
In conclusion, the dopaminergic system, which involves the dopaminergic amacrine cells and 
their post-synaptic cells, is affected in PD and this retinal degeneration may explain not only 
visual but also motor and circadian rhythm alterations suffered by PD patients. Thus, eye care 
and protection to preserve retinal cells, retinal pharmacological treatment, or chronotherapies to 
stimulate mRGC and retinal dopamine release, may have a positive impact in the disease 
progression. Also, visual exams should be considered during PD diagnosis and follow-up, as 
visual changes may partially reflect the retinal state and hence the PD neurodegenerative process. 
This study also reinforces the idea that retinal pathology may be considered as a biomarker of 
Parkinson disease.  
 
Acknowledgements 
This work was supported by the Michael J. Fox Foundation for Parkinson’s Research. IOL and 
XSS acknowledge financial support from the Ministerio de Educación, Spain (FPU 14/03166; 
FPU 16/04114). NC acknowledges financial support from the Ministerio de Economía y 
Competitividad, Spain (MINECO-FEDER-BFU2015-67139-R), Instituto de Salud Carlos III 
This article is protected by copyright. All rights reserved.
  
(RETICS-FEDER RD16/0008/0016), Asociación Retina Asturias, and Generalitat Valenciana-
FEDER (IDIFEDER/2017/064). The Brain and Body Donation Program has been supported by 
the National Institute of Neurological Disorders and Stroke (U24 NS072026), the National 
Institute on Aging (P30 AG19610), the Arizona Department of Health Services, the Arizona 
Biomedical Research Commission, and the Michael J. Fox Foundation for Parkinson’s Research.  
 
Author Contributions: IOL, TB, CA and NC contributed to the conception and design of the 
study; IOL, XSS, PL, GS, contributed to the acquisition and analysis of data; IOL, XSS, PL, GS, 
TB, CA and NC contributed to drafting the text and preparing the figures. 
Potential Conflicts of Interest: The authors declare that they have no conflict of interest. 
 
References 
1.  Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and 
alpha-synuclein. Nat. Rev. Neurosci. 2002;3(12):932–942. 
2.  Ortuño-Lizarán I, Beach TG, Serrano GE, et al. Phosphorylated α-Synuclein in the 
Retina is a Biomarker of Parkinson’s Disease Pathology Severity. Mov. Disord. 
2018;33(8):1315–1324. 
3.  Veys L, Vandenabeele M, Ortuño-Lizarán I, et al. Retinal α-synuclein deposits in 
Parkinson’s disease patients and animal models. Acta Neuropathol. 2019;137(3):379–
395. 
4.  Chrysou A, Jansonius NM, van Laar T. Retinal layers in Parkinson’s disease: A meta-
analysis of spectral-domain optical coherence tomography studies. Parkinsonism Relat. 
Disord. 2019;64:40–49. 
This article is protected by copyright. All rights reserved.
  
5.  Langheinrich T, Tebartz Van Elst L, Lagrèze WA, et al. Visual contrast response 
functions in Parkinson’s disease: Evidence from electroretinograms, visually evoked 
potentials and psychophysics. Clin. Neurophysiol. 2000;111(1):66–74. 
6.  Lin TP, Rigby H, Adler JS, et al. Abnormal visual contrast acuity in Parkinson’s disease. 
J. Parkinsons. Dis. 2015;5(1):125–30. 
7.  Nowacka B, Lubiński W, Honczarenko K, et al. Bioelectrical function and structural 
assessment of the retina in patients with early stages of Parkinson’s disease (PD). Doc. 
Ophthalmol. 2015;131(2):95–104. 
8.  Bohnen NI, Haugen J, Ridder A, et al. Color discrimination errors associate with axial 
motor impairments in Parkinson’s Disease. Mov. Disord. Clin. Pract. 2017;4(6):864–
869. 
9.  Gros P, Videnovic A. Overview of Sleep and Circadian Rhythm Disorders in Parkinson 
Disease. Clin. Geriatr. Med. 2020;36(1):119–130. 
10.  Leng Y, Musiek ES, Hu K, et al. Association between circadian rhythms and 
neurodegenerative diseases. Lancet. Neurol. 2019;18(3):307–318. 
11.  Ortuño-Lizarán I, Esquiva G, Beach TG, et al. Degeneration of human photosensitive 
retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s 
disease. Acta Neuropathol. Commun. 2018;6(1):1–10. 
12.  Zhang D-Q, Wong KY, Sollars PJ, et al. Intraretinal signaling by ganglion cell 
photoreceptors to dopaminergic amacrine neurons. Proc. Natl. Acad. Sci. U. S. A. 
2008;105(37):14181–14186. 
13.  Prigge CL, Yeh P-T, Liou N-F, et al. M1 ipRGCs Influence Visual Function through 
Retrograde Signaling in the Retina. J. Neurosci. 2016;36(27):7184–7197. 
14.  Van Hook MJ, Wong KY, Berson DM. Dopaminergic modulation of ganglion-cell 
This article is protected by copyright. All rights reserved.
  
photoreceptors in rat. Eur. J. Neurosci. 2012;35(4):507–518. 
15.  Liao HW, Ren X, Peterson BB, et al. Melanopsin-expressing ganglion cells on macaque 
and human retinas form two morphologically distinct populations. J. Comp. Neurol. 
2016;524(14):2845–2872. 
16.  Hampson EC, Vaney DI, Weiler R. Dopaminergic modulation of gap junction 
permeability between amacrine cells in mammalian retina. J. Neurosci. 
1992;12(12):4911–4922. 
17.  Deans MR, Volgyi B, Goodenough DA, et al. Connexin36 is essential for transmission 
of rod-mediated visual signals in the mammalian retina. Neuron 2002;36(4):703–712. 
18.  Nelson R, Kolb H. Amacrine cells in scotopic vision. Ophthalmic Res. 1984;16(1–
2):21–26. 
19.  Mariani AP, Kolb H, Nelson R. Dopamine-containing amacrine cells of rhesus monkey 
retina parallel rods in spatial distribution. Brain Res. 1984;322(1):1–7. 
20.  Kolb H, Cuenca N, Wang HH, Dekorver L. The synaptic organization of the 
dopaminergic amacrine cell in the cat retina. J. Neurocytol. 1990;19(3):343–366. 
21.  Jackson CR, Ruan G-X, Aseem F, et al. Retinal dopamine mediates multiple dimensions 
of light-adapted vision. J. Neurosci. 2012;32(27):9359–9368. 
22.  Beach TG, Adler CH, Sue LI, et al. Arizona Study of Aging and Neurodegenerative 
Disorders and Brain and Body Donation Program. Neuropathology 2015;35(4):354–389. 
23.  Beach TG, Sue LI, Walker DG, et al. The Sun Health Research Institute Brain Donation 
Program: Description and Eexperience, 1987–2007. Cell Tissue Bank. 2008;9(3):229–
245. 
24.  Gelb D, Oliver E, Gilman S. Diagnostic criteria for parkinson disease. Arch. Neurol. 
1999;56(1):33–39. 
This article is protected by copyright. All rights reserved.
  
25.  Provencio I, Rodriguez IR, Jiang G, et al. A novel human opsin in the inner retina. J 
Neurosci 2000;20(2):600–605. 
26.  Fasoli A, Dang J, Johnson JS, et al. Somatic and neuritic spines on tyrosine 
hydroxylase–immunopositive cells of rat retina. J. Comp. Neurol. 2017;525(7):1707–
1730. 
27.  Keeley PW, Reese BE. Morphology of dopaminergic amacrine cells in the mouse retina: 
independence from  homotypic interactions. J. Comp. Neurol. 2010;518(8):1220–1231. 
28.  Cuenca N, Deng P, Linberg KA, et al. The neurons of the ground squirrel retina as 
revealed by immunostains for calcium  binding proteins and neurotransmitters. J. 
Neurocytol. 2002;31(8–9):649–666. 
29.  Dacey DM. The dopaminergic amacrine cell. J. Comp. Neurol. 1990;301(3):461–489. 
30.  Guimarães PZ, Hokoç JN. Tyrosine hydroxylase expression in the Cebus monkey retina. 
Vis. Neurosci. 1997;14(4):705–715. 
31.  Lee SCS, Weltzien F, Madigan MC, et al. Identification of AⅡ amacrine, displaced 
amacrine, and bistratified ganglion cell  types in human retina with antibodies against 
calretinin. J. Comp. Neurol. 2016;524(1):39–53. 
32.  Cuenca N, Ortuño-Lizarán I, Pinilla I. Cellular Characterization of OCT and Outer 
Retinal Bands Using Specific Immunohistochemistry Markers and Clinical Implications. 
Ophthalmology 2018;125(3):407–422. 
33.  O’Brien JJ, Chen X, Macleish PR, et al. Photoreceptor coupling mediated by connexin36 
in the primate retina. J. Neurosci. 2012;32(13):4675–4687. 
34.  Rollag MD, Berson DM, Provencio I. Melanopsin, ganglion-cell photoreceptors, and 
mammalian photoentrainment. J. Biol. Rhythms 2003;18(3):227–234. 
35.  Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 
This article is protected by copyright. All rights reserved.
  
2016. 
36.  Wang HH, Cuenca N, Kolb H. Development of morphological types and distribution 
patterns of amacrine cells immunoreactive to tyrosine hydroxylase in the cat retina. Vis. 
Neurosci. 1990;4(2):159–175. 
37.  Dowling JE. Dopamine: a retinal neuromodulator? Trends Neurosci. 1986;9:236–240. 
38.  Witkovsky P, Dearry A. Functional roles of dopamine in the vertebrate retina. Prog. 
Retin. Res. 1991;11:247–292. 
39.  Kolb H, Cuenca N, Dekorver L. Postembedding immunocytochemistry for GABA and 
glycine reveals the synaptic relationships of the dopaminergic amacrine cell of the cat 
retina. J. Comp. Neurol. 1991;310(2):267–284. 
40.  Witkovsky P. Dopamine and retinal function. Doc. Ophthalmol. 2004;108(1):17–40. 
41.  Popova E. Role of dopamine in distal retina. J. Comp. Physiol. A. Neuroethol. Sens. 
Neural. Behav. Physiol. 2014;200(5):333–58. 
42.  Bloomfield SA. Plasticity of AII amacrine cell circuitry in the mammalian retina. Prog. 
Brain Res. 2001;131:185–200. 
43.  Bloomfield SA, Dacheux RF. Rod vision: pathways and processing in the mammalian 
retina. Prog. Retin. Eye Res. 2001;20(3):351–384. 
44.  Kolb H, Zhang L, Dekorver L, Cuenca N. A new look at calretinin-immunoreactive 
amacrine cell types in the monkey retina. J. Comp. Neurol. 2002;453(2):168–184. 
45.  Strettoi E, Raviola E, Dacheux RF. Synaptic connections of the narrow-field, bistratified 
rod amacrine cell (AII) in the rabbit retina. J. Comp. Neurol. 1992;325(2):152–168. 
46.  Trexler EB, Li W, Mills SL, Massey SC. Coupling from AII amacrine cells to ON cone 
bipolar cells is bidirectional. J. Comp. Neurol. 2001;437(4):408–422. 
47.  Giannoccaro MP, La Morgia C, Rizzo G, Carelli V. Mitochondrial DNA and primary 
This article is protected by copyright. All rights reserved.
  
mitochondrial dysfunction in Parkinson’s disease. Mov. Disord. 2017;32(3):346–363. 
48.  Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the 
dysfunction of retinal dopaminergic circuitry in Parkinson’s disease. Surg. Radiol. Anat. 
1988;10(2):137–144. 
49.  Adam CR, Shrier E, Ding Y, et al. Correlation of Inner Retinal Thickness Evaluated by 
Spectral-Domain Optical Coherence Tomography and Contrast Sensitivity in Parkinson 
disease. J. Neuro-Ophthalmology 2013;33(2):137–142. 
50.  Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson’s 
disease. Invest. Ophthalmol. Vis. Sci. 1990;31(11):2473–2475. 
51.  Wong C, Ishibashi T, Tucker G, Hamasaki D. Responses of the pigmented rabbit retina 
to NMPTP, a chemical inducer of parkinsonism. Exp. Eye Res. 1985;40(4):509–519. 
52.  Ghilardi MF, Chung E, Bodis-Wollner I, et al. Systemic 1-methyl,4-phenyl,1-2-3-6-
tetrahydropyridine (MPTP) administration decreases retinal dopamine content in 
primates. Life Sci. 1988;43(3):255–262. 
53.  Mariani AP, Neff NH, Hadjiconstantinou M. 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) treatment decreases dopamine  and increases lipofuscin in 
mouse retina. Neurosci. Lett. 1986;72(2):221–226. 
54.  Tatton WG, Kwan MM, Verrier MC, et al. MPTP produces reversible disappearance of 
tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 1990;527(1):21–31. 
55.  Peoples C, Shaw VE, Stone J, et al. Survival of Dopaminergic Amacrine Cells after 
Near-Infrared Light Treatment in  MPTP-Treated Mice. ISRN Neurol. 
2012;2012:850150. 
56.  Cuenca N, Herrero M-T, Angulo A, et al. Morphological impairments in retinal neurons 
of the scotopic visual pathway in a monkey model of Parkinson’s disease. J. Comp. 
This article is protected by copyright. All rights reserved.
  
Neurol. 2005;493(2):261–273. 
57.  Esteve-Rudd J, Fernández-Sánchez L, Lax P, et al. Rotenone induces degeneration of 
photoreceptors and impairs the dopaminergic system in the rat retina. Neurobiol. Dis. 
2011;44(1):102–115. 
58.  Biehlmaier O, Alam M, Schmidt WJ. A rat model of Parkinsonism shows depletion of 
dopamine in the retina. Neurochem. Int. 2007;50(1):189–195. 
59.  Meng T, Zheng ZH, Liu TT, Lin L. Contralateral retinal dopamine decrease and 
melatonin increase in progression of hemiparkinsonium rat. Neurochem. Res. 
2012;37(5):1050–1056. 
60.  Marrocco E, Esposito F, Tarallo V, et al. α-synuclein in the retina leads to degeneration 
of dopamine amacrine cells impairing vision. bioRxiv 2019; 
61.  Beach TG, Carew J, Serrano G, et al. Phosphorylated α-synuclein-immunoreactive 
retinal neuronal elements in Parkinson’s disease subjects. Neurosci. Lett. 2014;571:34–
38. 
62.  Armstrong RA. Visual Dysfunction in Parkinson’s Disease. Int. Rev. Neurobiol. 
2017;134:921–946. 
63.  Guo L, Normando EM, Shah PA, et al. Oculo-visual abnormalities in Parkinson’s 
disease: Possible value as biomarkers. Mov. Disord. 2018;33(9):1390–1406. 
64.  Safranow K. Ophthalmological Features of Parkinson Disease. Med. Sci. Monit. 
2014;20:2243–2249. 
65.  Nguyen-Legros J, Versaux-Botteri C, Vernier P. Dopamine receptor localization in the 
mammalian retina. Mol. Neurobiol. 1999;19(3):181–204. 
66.  Holopigian K, Clewner L, Seiple W, Kupersmith MJ. The effects of dopamine blockade 
on the human flash electroretinogram. Doc. Ophthalmol. 1994;86(1):1–10. 
This article is protected by copyright. All rights reserved.
  
67.  Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in 
Parkinson disease. Vision Res. 2004;44(24):2793–2797. 
68.  Willis GL, Moore C, Armstrong SM. Parkinson’s Disease, Lights and Melanocytes: 
Looking Beyond the Retina. Sci. Rep. 2015;4(1):3921. 
69.  Willis GL. Intraocular microinjections repair experimental Parkinson’s disease. Brain 
Res. 2008;1217:119–131. 
70.  Videnovic A, Klerman EB, Wang W, et al. Timed Light Therapy for Sleep and Daytime 
Sleepiness Associated With Parkinson Disease. JAMA Neurol. 2017;74(4):411. 
71.  Li Z, Tian T. Light Therapy Promoting Dopamine Release by Stimulating Retina in 
Parkinson Disease. JAMA Neurol. 2017;74(10):1267. 
72.  Videnovic A, Klerman EB, Zee PC. Light therapy promoting dopamine release by 
stimulating retina in parkinson disease - Reply. JAMA Neurol. 2017;74(10):1268–1269. 
 
  
This article is protected by copyright. All rights reserved.
  
Figure legends 
Fig. 1 Dopaminergic cells display an impaired morphology in PD. Dopaminergic cells (green) in 
healthy retinas (A) have long thin dendrites that create a dense plexus with ring structures (arrows) 
surrounding their post-synaptic cell bodies. In PD (B), dendrites are shorter and display some 
swollen regions (arrowheads), a sign of degeneration. Their plexus is less continuous, and it has 
lost the typical dopaminergic rings. In transversal sections, the density of the dopaminergic plexus 
can be observed in control (C) and PD (D) retinas. Dopaminergic plexus in control subjects (C) 
is much thicker, denser and more continuous than in PD patients (D). In addition, while a 
dopaminergic plexus at IPL S3 can be identified in controls, it is almost lost in PD, as are the few 
dopaminergic projections to S5 (arowheads). Dopaminergic projections towards the outer retina 
(OPL and ONL) can be observed in controls (C) but are strongly reduced in PD (D) (arrows). n=5 
control, n=8 PD. Scale bar A-D:10 µm. 
 
Fig. 2 Density of dopaminergic amacrine cells is reduced in PD. Color-coded density maps of 
dopaminergic cells in the macular region (temporal-central pieces) of control (A) and PD (B) 
reflect the decreased dopaminergic density in patients. Each dopaminergic cell is represented by 
a white or black dot and, in the color gradient, yellow represents the highest cell density (45 
cells/mm2) and dark blue the lowest (0 cells/mm2). Insets in (A) and (B) show high magnification 
images of the parafovea where changes in cell number between groups can be observed. Confocal 
images of dopaminergic amacrine cells in the parafovea of control (C) and PD (D) also show the 
decline in cell number observed in the disease. Dopaminergic cell density is highest at the 
parafovea, concentrically decreases towards higher eccentricities, and it is reduced in PD 
compared to controls in all the locations tested (E). In the temporal-central quadrant the 
dopaminergic density decreased from 20.2 cells/mm2 in controls to 13.1 cells/mm2 in PD, 
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changing from 45.1 in controls to 19.2 cells/mm2 in PD in the parafovea, from 29.7 cells/mm2 to 
14.4 cells/mm2 in the perifovea, and from 18.5 cells/mm2 to 12.9 cells/mm2 in the next 3mm.. In 
the superonasal quadrant, density maps of a representative area show the differences in 
dopaminergic cell density between control (F) and PD (G) and how the density is gradually 
reduced towards the periphery. This density is significantly reduced in PD, changing from 18.4 
cells/mm2 in the retina of healthy individuals to10.8 cells/mm2 in the retina of PD patients, and 
differences are maintained along the retina: from 2 to 7 mm to optic nerve dopaminergic cells 
change from 19.4 cells/mm2 in controls to 13.4 cells/mm2 in PD, from 7 to 11 mm to optic nerve 
it is reduced from 17.3 cells/mm2 in controls to 12.8 cells/mm2 in PD, and in the most peripheral 
region, from 11 to 16 mm to the optic nerve, dopaminergic density diminishes from 14.4 
cells/mm2 in controls to 8.8 cells/mm2 in PD, being statistically significant in all cases. ON: Optic 
Nerve; Fv: Fovea. A-E: n=3 control, n=2 PD; F-H: n=5 control, n=8 PD. Scale bar A-B, F-G: 
1mm; C-D: 20 µm. *: P<0.05; **: P<0.01.  
 
Fig. 3 AII amacrine cells maintain their cell density in PD although their dopaminergic inputs are 
reduced. Double immunostaining using tyrosine hydroxylase (TH, green) and calretinin (CR, red) 
shows the interactions between dopaminergic (green) and AII (red) amacrine cells. In control 
retinas (A), dopaminergic cells make several synaptic contacts around AII soma (arrows), which 
are severely lost in PD (B). High magnification images show the contacts and the ring structures 
in controls (C, D) and PD (E, F) (arrowheads). Their quantification revealed a significant loss of 
dopaminergic contacts per AII cell, from 9.3±0.2 in controls to 3.7±0.8 in PD (G) but no 
differences in the number of AII amacrine cells was observed (H). n=4 control, n=7 PD, H: 20 
different frames per retina. Scale bar A-B: 20 µm; C-F: 5 µm; **: P<0.01; n.s.: non-significant  
 
This article is protected by copyright. All rights reserved.
  
Fig. 4 AII amacrine cells loss mitochondria in their lobular appendages in PD. Calretinin (CR) 
shows AII amacrine cells (red) and cytochrome C (CytC) shows mitochondria in control (A) and 
PD (B) retinas. AII amacrine cells (red) present small dendrites that stratify close to the cell body 
in both sublamina a and b of the IPL (A). In PD, their typical morphology has been partially 
disrupted, showing an apparent loss of lobular appendages and stratification. Also, healthy 
subjects have big and abundant mitochondria within the AII lobular appendages (C, arrows) while 
fewer and smaller mitochondria are found in the retina of PD (D, arrows). Higher magnification 
images of the areas indicated by doted lines show differences in mitochondria size and number 
between controls, where lobular appendages are full of big mitocondria (E, arrows) and PD, where 
mitochondria are small, sparse (F, arrows) and some lobular appendages seem empty. n=3 control, 
n=5 PD. Scale bar A-D: 10 µm; E-F: 5 µm 
 
Fig. 5 AII amacrine cells in PD loss connexin 36 at the ON sublamina of the IPL. In healthy 
controls (A), AII (calretinin, CR, red) gap junctions are mediated by connexin 36 (Cx36, green), 
which is abundant at the IPL ON sublamina. In PD (B), connexin 36 is reduced, probably altering 
gap junctions. (C) and (D) are the same images as (A) and (B) respectively but showing the green 
channel alone, to properly observe the connexin 36 reduction in PD (D). (E-F) are high 
magnification images of (A-B) dotted areas. Notice the altered morphology of AII cells (less 
lobular appendages and impaired stratification) and the reduction in connexin 36 in PD (F) 
compared to controls (E). (G-H) images display the green channel from (E-F) images and are high 
magnification of (C-D); they show the strong decline in connexin 36 in the sublamina ON of the 
IPL in PD (H) compared to controls (G). n=3 control, n=5 PD Scale bar: A-D: 10 µm; E-F: 5 µm 
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Fig. 6 Dopaminergic synaptic contacts to melanopsin retinal ganglion cells are reduced in PD. In 
controls, melanopsin cells (red) display their normal morphology (A), while in PD cell dendrites 
are less complex, having lower number of branches and shorter dendrites (B). Also, controls 
display a dense dopaminergic plexus (green) (C), that is reduced in PD (D). In high-magnification 
images, details of synaptic contacts of dopaminergic cells in melanopsin dendrites can be 
observed (E-H), showing that controls (E, F) have a higher number of contacts than PD (G, H). 
Its quantification revealed a loss of dopaminergic synaptic contacts in melanopsin dendrites: from 
70±14 contacts per 100 µm in controls to 43±9 contacts per 100 µm in PD (P<0.0001) (i). n=3 
control, n=3 PD, 15 different frames per retina. Scale bar: A-D: 20 µm; E-H: 1 µm 
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Fig. 1 Dopaminergic cells display an impaired morphology in PD. Dopaminergic cells (green) in healthy 
retinas (A) have long thin dendrites that create a dense plexus with ring structures (arrows) surrounding 
their post-synaptic cell bodies. In PD (B), dendrites are shorter and display some swollen regions 
(arrowheads), a sign of degeneration. Their plexus is less continuous, and it has lost the typical 
dopaminergic rings. In transversal sections, the density of the dopaminergic plexus can be observed in 
control (C) and PD (D) retinas. Dopaminergic plexus in control subjects (C) is much thicker, denser and 
more continuous than in PD patients (D). In addition, while a dopaminergic plexus at IPL S3 can be 
identified in controls, it is almost lost in PD, as are the few dopaminergic projections to S5 (arowheads). 
Dopaminergic projections towards the outer retina (OPL and ONL) can be observed in controls (C) but are 
strongly reduced in PD (D) (arrows). n=5 control, n=8 PD. Scale bar A-D:10 m. 
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Fig. 2 Density of dopaminergic amacrine cells is reduced in PD. Color-coded density maps of dopaminergic 
cells in the macular region (temporal-central pieces) of control (A) and PD (B) reflect the decreased 
dopaminergic density in patients. Each dopaminergic cell is represented by a white or black dot and, in the 
color gradient, yellow represents the highest cell density (45 cells/mm2) and dark blue the lowest (0 
cells/mm2). Insets in (A) and (B) show high magnification images of the parafovea where changes in cell 
number between groups can be observed. Confocal images of dopaminergic amacrine cells in the parafovea 
of control (C) and PD (D) also show the decline in cell number observed in the disease. Dopaminergic cell 
density is highest at the parafovea, concentrically decreases towards higher eccentricities, and it is reduced 
in PD compared to controls in all the locations tested (E). In the temporal-central quadrant the dopaminergic 
density decreased from 20.2 cells/mm2 in controls to 13.1 cells/mm2 in PD, changing from 45.1 in controls 
to 19.2 cells/mm2 in PD in the parafovea, from 29.7 cells/mm2 to 14.4 cells/mm2 in the perifovea, and 
from 18.5 cells/mm2 to 12.9 cells/mm2 in the next 3mm.. In the superonasal quadrant, density maps of a 
representative area show the differences in dopaminergic cell density between control (F) and PD (G) and 
how the density is gradually reduced towards the periphery. This density is significantly reduced in PD, 
changing from 18.4 cells/mm2 in the retina of healthy individuals to10.8 cells/mm2 in the retina of PD 
patients, and differences are maintained along the retina: from 2 to 7 mm to optic nerve dopaminergic cells 
change from 19.4 cells/mm2 in controls to 13.4 cells/mm2 in PD, from 7 to 11 mm to optic nerve it is 
reduced from 17.3 cells/mm2 in controls to 12.8 cells/mm2 in PD, and in the most peripheral region, from 
11 to 16 mm to the optic nerve, dopaminergic density diminishes from 14.4 cells/mm2 in controls to 8.8 










cells/mm2 in PD, being statistically significant in all cases. ON: Optic Nerve; Fv: Fovea. A-E: n=3 control, 
n=2 PD; F-H: n=5 control, n=8 PD. Scale bar A-B, F-G: 1mm; C-D: 20 m. *: P<0.05; **: P<0.01. 
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Fig. 3 AII amacrine cells maintain their cell density in PD although their dopaminergic inputs are reduced. 
Double immunostaining using tyrosine hydroxylase (TH, green) and calretinin (CR, red) shows the 
interactions between dopaminergic (green) and AII (red) amacrine cells. In control retinas (A), dopaminergic 
cells make several synaptic contacts around AII soma (arrows), which are severely lost in PD (B). High 
magnification images show the contacts and the ring structures in controls (C, D) and PD (E, F) 
(arrowheads). Their quantification revealed a significant loss of dopaminergic contacts per AII cell, from 
9.30.2 in controls to 3.70.8 in PD (G) but no differences in the number of AII amacrine cells was 
observed (H). n=4 control, n=7 PD, H: 20 different frames per retina. Scale bar A-B: 20 m; C-F: 5 m; 
**: P<0.01; n.s.: non-significant 












Fig. 4 AII amacrine cells loss mitochondria in their lobular appendages in PD. Calretinin (CR) shows AII 
amacrine cells (red) and cytochrome C (CytC) shows mitochondria in control (A) and PD (B) retinas. AII 
amacrine cells (red) present small dendrites that stratify close to the cell body in both sublamina a and b of 
the IPL (A). In PD, their typical morphology has been partially disrupted, showing an apparent loss of lobular 
appendages and stratification. Also, healthy subjects have big and abundant mitochondria within the AII 
lobular appendages (C, arrows) while fewer and smaller mitochondria are found in the retina of PD (D, 
arrows). Higher magnification images of the areas indicated by doted lines show differences in mitochondria 
size and number between controls, where lobular appendages are full of big mitocondria (E, arrows) and PD, 
where mitochondria are small, sparse (F, arrows) and some lobular appendages seem empty. n=3 control, 
n=5 PD. Scale bar A-D: 10 m; E-F: 5 m 












Fig. 5 AII amacrine cells in PD loss connexin 36 at the ON sublamina of the IPL. In healthy controls (A), AII 
(calretinin, CR, red) gap junctions are mediated by connexin 36 (Cx36, green), which is abundant at the IPL 
ON sublamina. In PD (B), connexin 36 is reduced, probably altering gap junctions. (C) and (D) are the same 
images as (A) and (B) respectively but showing the green channel alone, to properly observe the connexin 
36 reduction in PD (D). (E-F) are high magnification images of (A-B) dotted areas. Notice the altered 
morphology of AII cells (less lobular appendages and impaired stratification) and the reduction in connexin 
36 in PD (F) compared to controls (E). (G-H) images display the green channel from (E-F) images and are 
high magnification of (C-D); they show the strong decline in connexin 36 in the sublamina ON of the IPL in 
PD (H) compared to controls (G). n=3 control, n=5 PD Scale bar: A-D: 10 m; E-F: 5 m 












Fig. 6 Dopaminergic synaptic contacts to melanopsin retinal ganglion cells are reduced in PD. In controls, 
melanopsin cells (red) display their normal morphology (A), while in PD cell dendrites are less complex, 
having lower number of branches and shorter dendrites (B). Also, controls display a dense dopaminergic 
plexus (green) (C), that is reduced in PD (D). In high-magnification images, details of synaptic contacts of 
dopaminergic cells in melanopsin dendrites can be observed (E-H), showing that controls (E, F) have a 
higher number of contacts than PD (G, H). Its quantification revealed a loss of dopaminergic synaptic 
contacts in melanopsin dendrites: from 7014 contacts per 100 m in controls to 439 contacts per 100 
m in PD (P<0.0001) (i). n=3 control, n=3 PD, 15 different frames per retina. Scale bar: A-D: 20 m; E-
H: 1 m 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
